Exonate announces the formation of ophthalmology Clinical Advisory Board (“Exonate” or the “Company”)

Ophthalmology leaders to support early stage biotechnology company with potential to revolutionise current standard-of-care in the treatment of eye diseases   Cambridge, UK – 8 November: Exonate, an early stage biotechnology company, today announces the formation of its Clinical Advisory Board (CAB) to support the scientific, pre-clinical development of a revolutionary eye-drop treatment for retinal…

Exonate receives Wellcome Trust funding to develop eye drop treatment for wet age-related macular degeneration (wet AMD)

Early stage biotechnology company targeting ophthalmology and other areas of unmet medical need   Cambridge, UK. Monday 6th February 2017 – Exonate, an early stage biotechnology company has been awarded a £4.9m Seeding Drug Discovery award by the Wellcome Trust to continue development of an eye – drop treatment for wet age–related macular degeneration.  …

Exonate closes successful funding round – to develop eye drops treatment for wet age-related macular degeneration (wet AMD)

Exonate closes successful funding round – to develop eye drops treatment for wet age-related macular degeneration (wet AMD) New and existing investors participated in the round Early stage biotechnology company targeting ophthalmology and other areas of unmet medical need Cambridge, UK. Wednesday [30th] November 2016 – Exonate, an early stage biotechnology company, today announced they…